Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Kinrix booster co-administered with varicella and MMR vaccines in healthy children aged 4 to 6 years
2011-002946-11Phase 3
- Sponsor
- GSK
- Start
- May 2015
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics, Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in diphtheria, Tetanus, pertussis and 5 more comparing Kinrix + Varivax + M-M-R II with Kinrix + M-M-R II (2 arms). Primary endpoints: Booster responses for diphtheria, tetanus, PT, FHA, and PRN and Poliovirus geometric mean titres.
02
Drugs
Bordetella pertussis toxoid antigen (glutaraldehyde inactivated)varicella virus vaccine liveM-M-R II
03
Conditions
diphtheriaTetanuspertussispoliomyelitischickenpox
Beyond the preview
Go deeper on 2011-002946-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002946-11.